FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Ahlem, et al.	
USE SEVERAL SHEETS IF NECESSARY	FILING DATE 3/1/02	GROUP 1616

(Stamp: O I P E — JUN 2 5 2004 — PATENT & TRADEMARK OFFICE)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,412,953	11/01/83	Winters			
		3,155,690	11/03/64	Cole			
		3,187,022	06/01/65	Morrow			
		3,137,710	05/16/64	de Ruggieri			

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL		DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

EXAMINER INITIAL		OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Ben-Nathan, D. "Protection by dehydroepiandrosterone in mice infected with viral encephalitis", *Arch. Virol.*, Vol 120 (3-4), pp. 263-71 (1991)
		Rasmussen, K., et al, "Effects of dehydroepiandrosterone in immunosuppressed adult mice infected with cryptosporidium parvum", *J. Parasitol*, Vol. 81 (3), pp. 429-33 (1995)
		Woods, M., et al, "Treatment of aged mice with dehydroepiandrosterone provides an adjuvant effect in the immunization with recombinant hepatitis B surface antigen", *J. Immunol,* Vol. 150 (8)(2), pp. 77a (1993)
		Flouret, G., et al, "17-Aminoacylamido steroid antidepressants", *J of Medicinal Chem*, 1972, Vol. 15 (12), pp. 1281-83 (1972)
		Stickney, D., et al, "HE2100 and HE3204 protect rhesus macaques form chemotherapy or radiation induced myelosuppression", 40th Annual Meeting American Society of Clinical Oncology, *Proceedings of ASCO* (poster and abstract 6668),Vol. 23, pp. 597 (2004)

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.